EVE – Extracellular Vesicle Ecosystem for Theranostic Platforms
The EVE ecosystem has been established to promote and translate academic extracellular vesicle (EV) inventions from Finnish academic research organisations into new biomedicines and SME companies, with the potential to globally expand the EV market.
Blood cell derived EVs hold great potential as a new drug delivery vehicle, and comprise a novel business area for pharma. Further modification and development of these EV products, combined with specific biomolecules, offer real value in overcoming obstacles hampering targeted drug delivery to the CNS and for the treatment of cancer.
In combination with specific disease biomarkers, EVs offer an excellent theranostic instrument for early diagnosis and treatment monitoring. In a globally expanding market of EV biomarkers tools still need to be developed for their clinical translation. EVE brings together Finnish SMEs and their individual technological assets to enhance the sensitivity of EV characterisation and improve disease diagnostics, creating an asset for the global market.
